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Background: The initial treatment of acute necrotizing pancreatitis is conservative. Intervention
is indicated in patients with (suspected) infected necrotizing pancreatitis. In the Netherlands, the
standard intervention is necrosectomy by laparotomy followed by continuous postoperative lavage
(CPL). In recent years several minimally invasive strategies have been introduced. So far, these
strategies have never been compared in a randomised controlled trial. The PANTER study
(PAncreatitis, Necrosectomy versus sTEp up appRoach) was conceived to yield the evidence
needed for a considered policy decision.
Methods/design: 88 patients with (suspected) infected necrotizing pancreatitis will be randomly
allocated to either group A) minimally invasive 'step-up approach' starting with drainage followed,
if necessary, by videoscopic assisted retroperitoneal debridement (VARD) or group B) maximal
necrosectomy by laparotomy. Both procedures are followed by CPL. Patients will be recruited
from 20 hospitals, including all Dutch university medical centres, over a 3-year period. The primary
endpoint is the proportion of patients suffering from postoperative major morbidity and mortality.
Secondary endpoints are complications, new onset sepsis, length of hospital and intensive care stay,
quality of life and total (direct and indirect) costs. To demonstrate that the 'step-up approach' can
reduce the major morbidity and mortality rate from 45 to 16%, with 80% power at 5% alpha, a total
sample size of 88 patients was calculated.
Discussion: The PANTER-study is a randomised controlled trial that will provide evidence on the
merits of a minimally invasive 'step-up approach' in patients with (suspected) infected necrotizing
pancreatitis.
Background
The initial treatment of acute necrotizing pancreatitis is
conservative [1-4]. Once (peri-)pancreatic necrosis
becomes infected mortality increases steeply [3,4]. Inter-
vention is indicated when infection of (peri-)pancreatic
necrosis is proven by fine needle aspiration (FNA), when
(peri-)pancreatic air collections in the necrotic cavity are
depicted on computer tomography (CT) scan or when
sepsis persists despite maximal support on the intensive
care unit. Surgical intervention within the first 14 days
after the onset of symptoms should be averted because of
notoriously poor outcome in this phase of disease [4,5].
Organ failure needing intensive care treatment during the
first two weeks should be interpreted as a complication of
a systemic inflammatory response syndrome (SIRS).
There is no consensus in the literature on the optimal sur-
gical strategy in infected necrotizing pancreatitis. In a
recent systematic review we demonstrated that necrosec-
tomy by laparotomy was accompanied by high mortality
rates (15–27%) and considerable morbidity [6].
In recent years radiologists, gastrointestinal surgeons and
gastroenterologists have adopted minimally invasive
strategies in infected necrotizing pancreatitis [7]. Initially
only practiced in patients unfit for laparotomy, but in
recent years indications seem to have expanded [8-11].
Percutaneous catheter drainage (PCD)  [12-14]. endo-
scopic transgastric procedures [15,16]. and minimally
invasive necrosectomy [9-11]. have been proposed as
alternatives for necrosectomy by laparotomy. Although
preliminary results are promising, current series are small,
poorly comparable and a selection bias may have influ-
enced the results [7].
It has been reported that PCD obviates the need for surgi-
cal intervention in infected necrotizing pancreatitis in 30
to 100 per cent of cases  [12-14]. In these series committed
radiologists repeatedly performed repeated drainage pro-
cedures using large bore catheters. It has been argued that
because of the need for repeated procedures PCD can not
easily be implemented in clinical practice [17]. However,
we hypothesize that 'simple' drainage with regular bore
(12–14 French) percutaneous catheters can also be bene-
ficial to the patient. Drainage of 'infected fluid under pres-
sure' may help the patient in dealing with the (peri-
)pancreatic necrosis and delay or even obviate surgical
intervention in a relevant proportion of patients.
This article is available from: http://www.biomedcentral.com/1471-2482/6/6
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center study was performed in 11 hospitals in the Nether-
lands [8]. The outcome of the different interventional
strategies in (infected) necrotizing pancreatitis was
assessed. The strategy most often used was laparotomy
with continuous postoperative lavage (CPL) (53/106
patients) [8]. Of the patients treated with minimally inva-
sive surgery (n = 18), two-thirds had PCD prior to surgical
intervention. During surgery the percutaneous drain was
used as a 'guide wire' to facilitate retroperitoneal access to
the infected collections. The results of minimally invasive
surgery were favourable: 11% mortality as compared to
25% after laparotomy and CPL. However, since selection
bias may have played a role in the favourable results a ran-
domised controlled trial is warranted in order to define
evidence-based surgery in infected necrotizing pancreati-
tis.
We anticipate that a minimally invasive 'step-up
approach' results in a reduction in postoperative major
morbidity and mortality. The PANTER trial is designed to
compare a minimally invasive 'step-up approach'with a
primary maximal necrosectomyby laparotomy. The 'step-
up approach' consists of percutaneous or transgastric
drainage when necessary followed by minimally invasive
necrosectomy.
Methods/design
Study objectives
To test the hypothesis that a minimally invasive 'step-up
approach' will lead to a reduction of postoperative major
morbidity and mortality in patients with infected (peri-
)pancreatic necrosis.
Primary endpoint
The primary endpoint is the proportion of patients with
major morbidity or mortality, see Tables 1 and 2. Compli-
cations occurring subsequent to the first intervention after
randomisation until three months after discharge from
the hospital are compared.
Secondary endpoints
Secondary endpoints are 'minor' complications (such as
pancreatic fistula, pancreatic pseudocyst requiring inter-
vention, pancreatic abscess, biliary strictures, incisional
hernia requiring re-intervention and pancreatic insuffi-
ciency), new onset sepsis, new onset SIRS, total number of
interventions, hospital and intensive care stay, quality of
life and total (direct and indirect) costs.
Definitions
The definitions of the Atlanta classification are used. Pan-
creatic necrosis: focal area's of non-enhancing pancreatic
parenchyma on contrast-enhanced computer tomography
(CECT). Infected necrotizing pancreatitis: a positive culture
of pancreatic or peripancreatic necrosis obtained by FNA
or the presence of air in the collections on CECT. Suspected
infected necrotizing pancreatitis: persisting sepsis or progres-
sive clinical deterioration despite maximal support on the
intensive care unit in case of pancreatic and/or peripancre-
atic necrosis.
Design of study
PANTER is a randomised controlled parallel group superi-
ority multicenter trial.
Participating centres
Twenty hospitals of the Dutch Acute Pancreatitis Study
Group, including all Dutch university medical centres,
will enrol patients (see Appendix).
Pre-randomisation treatment protocol
All patients with acute pancreatitis will be treated by a pre-
established treatment protocol consisting of enteral nutri-
tion via a nasojejunal tube and an early endoscopic retro-
Table 1: Primary outcome of the PANTER trial; complications 
after first intervention
Mortality
New-onset multi organ failure or systemic complications #
Enteric fistula (either small or large bowel)
Perforation of a visceral organ requiring intervention
Bleeding requiring intervention*
# New onset failure of 2 or more organ systems or systemic 
complications as listed in Table 2, occurring at the same moment in 
time.
*Surgical, endoscopic or radiological
Table 2: Definitions of organ failure and systemic complications
Organ Failure Circulatory Systolic blood pressure less than 90 mm hg or need for catecholamine support
Pulmonary PaO2 60 mm Hg or less or need for mechanical ventilation
Renal creatinine level greater than 177 umol/L after rehydration or or need for 
hemofiltration or hemodialysis
Systemic complications Gastrointestinal bleeding more than 500 ml/24 hours
Disseminated intravascular coagulation platelets <100 × 109/L
Severe metabolic disturbance calcium level <1.87 mmol/LPage 3 of 10
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sphincterotomy in case of predicted severe biliary pancre-
atitis with or without obstructive cholangitis. No antibi-
otic prophylaxis will be administered. CECT will be
performed in patients who fail to show clinical improve-
ment after the first 7 days of hospital admission. Since
many patients are referred from other centres, violation of
the pre-randomisation treatment protocol is not an exclu-
sion criteria.
Registration
From all patients with (peri-)pancreatic necrosis, includ-
ing those who are not randomised and treated conserva-
tively, written informed consent will be obtained for
prospective registration of age, gender, onset of symp-
toms, interventional procedures, hospital stay, intensive
care stay and mortality (alternatively consent by proxy
will be obtained for patients who are unable to give con-
sent eg. intubated patients).
Timing of intervention
Whenever possible it is attempted to delay surgical inter-
vention. Ideally, the first intervention would be per-
formed at least 30 days after onset of symptoms. Earlier
intervention may be warranted in case of a rapidly deteri-
orating clinical condition. When infection is proven
within the first 14 days, intervention may be postponed.
Intervention within 14 days is only indicated in emergen-
cies such as bowel perforation, abdominal compartment
syndrome or acute bleeding. Patients with these complica-
tions are not eligible for randomisation.
Eligibility criteria
Inclusion criteria
▪ age equal to or above 18 years
▪ pancreatic necrosis or peripancreatic necrosis detected
on CECT.
▪ patients in whom a decision for surgical intervention has
been made because of (suspected) infected (peri-)pancre-
atic necrosis
▪ possibility of placing a drain (either percutaneous or
endoscopic) in the collection(s)
▪ written informed consent
Exclusion criteria
▪ previous drainage or surgical necrosectomy for (sus-
pected) infected pancreatic necrosis, including procedures
performed in referring hospitals. ERCP with or without
papillotomy is allowed.
▪ previous exploratory laparotomy for acute abdomen and
diagnosis of pancreatitis during laparotomy
▪ acute flare-up of chronic pancreatitis
▪ bleeding, abdominal compartment syndrome or perfo-
ration of a visceral organ as indication for intervention
▪ post-abdominal surgery necrotizing pancreatitis
Rationale: previous drainage procedures or laparotomy
make it impossible to study the isolated effect of drainage
of 'infected fluid under pressure'. There is essentially no
indication for necrosectomy in acute fluid collections,
pancreatic abscesses or pseudocysts as these collections do
not contain pancreatic necrosis or necrotic debris accord-
ing to the Atlanta Classification. When intervention is
indicated in these types of collections this is performed by
drainage procedures, although some pseudocysts may
require surgical intervention [4]. Patients with chronic
pancreatitis have an underlying disease with a course very
different from acute pancreatitis. Patients with a second,
third or fourth attack of acute pancreatitis are eligible for
randomisation as long as there are no signs of chronic
pancreatitis (calcification and/or pancreatic duct abnor-
malities).
Randomisation
Patients will be randomly assigned to group A ('step-up
approach') or group B (laparotomy) as shown in the flow-
chart (see figure 1). Randomisation is performed by an
Internet randomisation module (Julius Center for pri-
mary care and health sciences, UMC Utrecht, the Nether-
lands). Block-randomisation is used and the
randomisation is stratified according to the (im-)possibil-
ity of placing a percutaneous drain through the (prefera-
bly left) retroperitoneum, since this step is essential to
perform minimally invasive necrosectomy.
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The independent medical ethics committees
of all 20 participating hospitals have approved the study
protocol. Prior to randomisation, written informed con-
sent will be obtained from all patients (alternatively con-
sent by proxy will be obtained for patients who are unable
to give consent, e.g., intubated patients).
Safety and quality control
The indication and timing of intervention in necrotizing
pancreatitis can be difficult. Therefore, prior to randomi-
sation using CECT images and a 'summarized case report'
an expert panel consisting of three surgeons (MAB, HSH,
HGG), a gastroenterologist (RT) and three radiologistsPage 4 of 10
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of surgical, gastroenterological or radiological interven-
tion. All procedures will be performed by experienced
radiologists, gastroenterologists or gastrointestinal sur-
geons. All endo-/videoscopic procedures will be video-
taped. In case of a planned intervention, surgeons or
radiologists from (neighbouring) participating hospitals
and the trial coordinator will join the procedure in order
to increase experience and enhance protocol-compliance.
Every four months a study group meeting will be organ-
ised in which the CECT images and the 'summarized case
report' of all newly randomised patients will be discussed.
An independent monitoring-committee, consisting of two
surgeons, a gastroenterologist, an epidemiologist and a
radiologist, will discuss (serious) adverse events and give
advice to the trial steering committee.
Statistical analysis
Intention-to-treat
The analysis will be performed in accordance with inten-
tion-to-treat (ITT) principle
Sample size and sequential interim-analysis
Sequential analysis is used to determine the difference in
treatment effect on the primary endpoint (see Methods/
design section), therefore no fixed sample size estimate
can be given [18]. Based on the results of the Dutch retro-
spective multicentre audit (mortality 25% versus 11%)
and PCD results from the literature is anticipated that the
minimally invasive 'step-up approach' will reduce the
occurrence of the primary endpoint from 45% to 16%.
The expected reduction of mortality and morbidity are
10% and 19% respectively. With 80% power at 5% alpha
(two-sided) complete data from about 52–77 patients will
be necessary to demonstrate this effect, if it truly exists. If
no such effect appears, the trial will continue until 88
patients are randomised and available for analysis as 'con-
ventional' sample size calculation with 80% power at 5%
alpha (two-sided) would require 88 patients.
Descriptive methods will be used to assess the quality of
the data, comparability of treatment groups and end-
points. Continuous sequential analysis will be performed
with PEST (PEST 4: user manual. MPS Research Unit
(2000), the University of Reading) according to the
restricted procedure as described by Whitehead [18].
Every time an endpoint occurs, data management will
send a blinded, updated dataset of all included patients to
the biostatistician. If one of the boundaries of the sequen-
tial analysis plot is crossed during the analysis of the
cumulative data, i.e. the difference in treatment is of at
least the expected magnitude, the trial steering committee
will be informed and will be advised to stop randomising
new patients for the trial. The trial steering committee will
not be advised to stop early when no relevant differences
between the treatments are observed. Next to the primary
analysis, the outcome of both groups will also be adjusted
forimbalance in presence of preoperative (multi-) organ
PANTER according to CONSORTFigure 1
PANTER according to CONSORT.
To be assessed for 
eligibility (n=151) 
To be randomised 
(n=90)* 
Not meeting randomisation 
criteria (n=38)  
Refusal to participate (n=15) 
Other reasons (n=8) 
Allocated to a ‘step-up approach’ (n=45) 
Complete data (n=44) Complete data (n=44) 
Lost to follow up (n=1) 
Allocated to laparotomy (n=45)  
Lost to follow up (n=1) Page 5 of 10
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factors, including possibility of performing VARD and the
individual components of the primary endpoint will also
be included in a multivariate and subgroupanalysis.
Feasibility
The recent retrospective survey showed that in a 3-year
period 106 patients had undergone surgery for necrotiz-
ing pancreatitis in 11 of the 20 participating Dutch hospi-
tals [8]. It is expected that up to 25% of eligible patients
will be excluded mainly because of interventions (percu-
taneous drainage or surgery) being performed prior to
randomisation in referring centres. Taking further into
account refusal of informed consent (10%), other reasons
for drop-out (5%) and loss-to-follow-up (2.5%) it is con-
sidered possible to randomise and collect data on 88
patients in 3 years time. After one year, the inclusion rate
will be assessed. If accrual is too slow, additional centres
will be invited to participate.
Post-randomisation treatment protocol
All patients receive oral nutrition. If this is not tolerated, a
nasojejunal feeding tube is introduced and enteral feeding
is started [19]. If gastrointestinal feeding is contra-indi-
cated, the patient will receive parenteral nutrition. Antibi-
otic treatment, Imipenem-cilastatin therapy 500 mg 3
times daily, is started in all patients with a maximum
duration of fourteen days. Antibiotic treatment is
switched based on blood cultures and culture from mate-
rial collected during drainage and/or surgical procedures.
If cultures remain negative antibiotic treatment is
stopped. Selective decontamination of the digestive tract
is allowed.
Group A: minimally invasive 'step-up approach'
Step 1: Drainage
A percutaneous drain (at least 12 French) is placed in the
(peri-)pancreatic collection. Multiple drains may be indi-
cated in case of large or multiple collections. The preferred
route is through the left retroperitoneum. If this is not
possible a transperitoneal route is chosen. A right retro-
peritoneal route is allowed when it can be safely applied.
If this is also not possible, an endoscopic transgastric
drainage is performed with two 10 French drains (10
French being the current maximal drain size for endo-
scopic procedures) including a nasocystic drain for flush-
ing. No continuous lavage system is installed. Drains are
kept open by flushing with 50 ml saline once every 8-hrs
shift by nursing staff. Extra saline may be used depending
on the aspect of the return-fluid, the size of the collections
on CECT, communication between drains and connec-
tions between collections. If more than 200 ml saline is
used daily a drain fluid-balance chart is kept.
If there is no clinical improvement 72 hours after drain
placement, this is considered a failure and a CECT is made
to check the position of the drain. "Clinical improve-
ment" is defined as: improved function of at least two
organ systems (circulatory, pulmonary, renal) within 72
hours, or at least 10% improvement of two out of three
parameters: leucocytes/temperature/CRP. If during the
repeat CECT the position of the drain is adequate and no
additional drainable collections are seen, the patient is
taken to the operating room (step two). If the position of
the drain is inadequate a second drain is placed in the col-
lection.
Seventy-two hours after a second drainage-procedure the
patient is again evaluated. In case of improvement, treat-
ment is conservative; otherwise the patient will be taken
to the operating room (step two). If after drainage, at any
moment in time, a deterioration of at least two organ sys-
tems (circulatory, pulmonary, renal), or at least 10% dete-
rioration of two out of three parameters: leucocytes/
temperature/CRP occurs, step two is taken. Deterioration
(of these parameters) by other infectious causes (e.g. an
urinary tract infection) should be excluded.
Step two: videoscopic assisted retroperitoneal debridement
The percutaneous retroperitoneal drain is used for video-
scopic assisted retroperitoneal debridement (VARD).
VARD has been used in several of the participating centres
since 2000. The technique was recently described by Hor-
vath et al[11]. See figure 2.
1. The patient is placed in a supine position with the left
side elevated.
2. The left flank and the entire abdomen are prepared and
draped.
3. Based on the position of the drain a 5 cm sub- or inter-
costal incision is made in the left flank.
4. With digital exploration the retroperitoneal drain is fol-
lowed into the collection.
5. The collection is opened and necrosectomy performed
with ring forceps and suction device.
6. A long 10 mm trocar and a 10 mm long zero degree vid-
eoscope (laparoscope) are inserted through the incision
in the retroperitoneum.
7. With the videoscope the cavity is inspected and remain-
ing, loosely adherent, necrosis is removed with a laparo-
scopic grasper or ring forceps. Note: it is not considered
mandatory to remove all necrotic material.Page 6 of 10
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tion via the incision and the skin is closed between the
drains.
If VARD is technically not feasible, laparotomy by bilat-
eral subcostal incisions is performed as in Group B. Out-
come of these patients will be analysed in group A
according to the intention-to-treat principles.
Group B: maximal necrosectomy by laparotomy
Laparotomy is performed with a bilateral subcostal inci-
sion. The lesser sac is entered through the omentum and
carefully inspected. Blunt debridement of all necrotic tis-
sue is performed. Two large bore drainage tubes are
inserted through separate incisions with their tips in the
lesser sac and necrotic cavities, the entrance to the lesser
sac is carefully closed to create a contained space for CPL
[20]. In case of diffuse bleeding, it is advisable to perform
packing with gauzes that are to be removed the next day.
Consequently, the lavage system is then installed on the
first postoperative day.
Both in group A and in group B, necrotic material is col-
lected during necrosectomy for culture and the total
amount of necrotic tissue collected is weighed and photo-
graphed.
Postoperative management
The postoperative management is similar in both groups.
Continuous postoperative lavage with normal saline or
peritoneal dialysis (CAPD) fluid is started. On the third
postoperative day, the lavage should amount to at least 10
PANTER flowchartFigure 2
PANTER flowchart. ® = randomisation. #In the intensive care: within 72 hours, improved function of at least two organ systems 
(renal/respiratory/cardiovascular) or in the ward: within 72 hours, improvement of two of these three parameters: leucocytes/
temperature/CRP. The worst parameter is used. §No clinical improvement within 72 hours after drainage is considered failure: 
repeat the CT-scan once to check position of the drains. If the position is adequate, and no additional drainable collections are 
seen, proceed to surgery, if drain position is inadequate: repeat CT-guided percutaneous drainage (or endoscopic transgastric 
drainage). If after the second drainage there is no clinical improvement within 72 hours, proceed to surgery. If repeat-drainage 
is not possible, patients proceed to surgery.
® 
Group A 
Minimally invasive ‘step up approach’
Group B 
Maximal necrosectomy
Videoscopic Assisted Retroperiteoneal Debridement (VARD)
If VARD is not possible, laparotomy similar to group B is performed.  
In both cases CPL >4L/24 hrs is installed 
In case of clinical improvement
# wait and see  
If no clinical improvement or deterioration, repeat CT-scan once
§
Laparotomy, maximal 
necrosectomy  
and continuous  
postoperative lavage 
(CPL) >4L/24hrs
Drain placement 
1. Percutaneous through left retroperitoneum (preferred strategy) 
2. Percutaneous transabdominal  
3. Endoscopic transgastric  
Check in- and exclusion criteria  
CT-scan: drain placement possible? Page 7 of 10
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every drain placement and surgical intervention. Cathe-
ters are removed if collapse of the cavity is shown on
CECT with contrast through the drainage system (or: on a
sinogram of the cavity), and daily production of clear flu-
ids has decreased below 50 ml/24 hours. Patients can be
discharged with catheters in place and continue irrigation
at home. Time to final removal of the drains will be
recorded.
Indication for re-intervention
Re-intervention is performed 'on-demand'. Planned re-
intervention is only performed in case 'packing materials'
have been left in-situ during the first procedure. A re-inter-
vention for removal of necrotic remnants is, whenever
technically feasible, performed in accordance with the
strategy the patient was initially assigned to. However, a
pancreatic abscess (a collection consisting only of pus
without necrosis) is treated by percutaneous drainage
only.
Data collection
Data are collected via a secured Internet module which
was specifically designed for the PANTER trial (Julius
Center for primary care and health sciences, UMC Utrecht,
the Netherlands). Data are entered online but are not
stored on the Internet. Sequential Organ Dysfunction
Scores (SOFA) are noted at randomisation [21,22]. The
SOFA score, major morbidity (Table 1) and other compli-
cations are registered every second day for the first month
and twice weekly thereafter until discharge. Furthermore
at any (re-)intervention the SOFA score, procedure-related
data (length of procedure, blood-loss) and procedure-
related complications are scored.
Data monitoring
There will be regular contact (by telephone, e-mail and
site-visits) between the study coordinators and participat-
ing centres. Two study nurses will monitor the entered
data. Twice a year a minimum of 10% of the data, includ-
ing all end points, will be verified (double-checked) with
source data at the study site by an independent monitor.
Follow-up
Patients are observed during their hospital stay. Follow-up
visits are planned after 3 and 6 months. For the primary
endpoint, follow-up is completed at 3 months and for the
secondary endpoints at 6 months after discharge, with a
physical examination to exclude incisional hernia and
ultrasonography to exclude a pancreatic pseudocyst.
Discussion
A recent Dutch retrospective multicenter study showed
that laparotomy with CPL is the current standard for treat-
ment of infected necrotizing pancreatitis as it is the tech-
nique most frequently used in the Netherlands with
consistently and relatively good results [8]. In this series,
mortality for the 'open-abdomen-strategy' was 70%
(intention-to-treat analysis) which is unacceptably high.
The 'experimental arm' in PANTER is a minimally invasive
'step-up approach'. Notably, in necrotizing pancreatitis a
minimally invasive approach does not only aim at mini-
mising surgical stress, it is also part of a different treatment
concept. We hypothesize that it is not necessary to remove
all necrotic tissue in order to successfully treat patients
with infected necrotizing pancreatitis. By performing
drainage of 'infected fluid under pressure' the clinical con-
dition may improve and the necrotic tissue may success-
fully be dealt with by the patient's immune system. It is
therefore not the goal of drainage to remove (peri-)pan-
creatic necrosis but merely the infected fluid.
The second step of the minimally invasive 'step-up
approach', 'VARD', is only performed if the first step fails.
VARD combines endoscopic 'drain-tract' necrosectomy as
first described by Carter et al[9]. and an open retroperito-
neal approach. In our opinion VARD has the advantage of
endoscopic necrosectomy as it is minimally invasive.
However, VARD lacks the disadvantages of being techni-
cally demanding and time consuming. In VARD the rela-
tively small 5 cm incision greatly facilitates the 'debulking'
part. This will not only reduce the operating time but also
potentially reduce the number of procedures needed to
remove the necrotic tissue.
It has been argued that minimally invasive procedures are
only feasible in a small subgroup of necrotizing pancrea-
titis patients. Our group recently performed a feasibility
study re-evaluating CT scans of 80 patients operated upon
for (suspected) infected necrotizing pancreatitis and
found that in the vast majority of patients PCD is techni-
cally feasible and that in the majority of patients VARD is
possible [23].
Currently, there are no randomised controlled trials com-
paring surgical techniques in necrotizing pancreatitis
most likely due to low patient volumes, the heterogeneity
of the disease and the highly individualized approach.
The Dutch Acute Pancreatitis Study Group was founded to
resolve several of these problems [24]. Since 2004, 15 of
the 20 centres participating in PANTER are also participat-
ing in PROPATRIA, a placebo-controlled trial of probiotic
prophylaxis in predicted severe acute pancreatitis [25].
Patients who initially are included in PROPATRIA are
screened for eligibility in PANTER. Once a patient devel-
ops infected necrotizing pancreatitis the outcome for
PROPATRIA is reached and he/she can be randomised for
PANTER. With this already ongoing multicenter coopera-
tion the logistical and organisational problems are
expected to be kept at a minimum.Page 8 of 10
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to stop the trial as soon as sufficient evidence has accumu-
lated regarding both clinically relevant and statistically
significant treatment difference. Compared to a conven-
tional fixed sample size sequential analysis on average
requires less patients to show an expected effect if it truly
exists [18]. This can be advantageous when the disorder is
as rare as infected necrotizing pancreatitis. Moreover, as
soon as the predefined threshold is passed randomisation
may seize, thus preventing further patients to be subjected
to an inferior treatment. If the presumed effect does not
exist, based on conventional sample size calculations, 88
patients will be randomised.
A possible disadvantage of the present study concept is the
large number of centres participating. In the Netherlands
centralisation has not reached a level that all patients are
referred to tertiary centres [8,26]. However, the 20 hospi-
tals participating are amongst the largest of the 101 Dutch
hospitals and all have experienced gastrointestinal sur-
geons, gastroenterologists and radiologists, including for
example interventional radiology facilities to treat immi-
nent bleeding. Furthermore, since in the Netherlands dis-
tances between any participating hospital and the nearest
university medical centre is always within 10–100 kilome-
tres, referral of patients is generally accepted and easy. A
second possible disadvantage is the exclusion criteria 'pre-
vious placement of percutaneous drains'. This may apply
to a considerable number of patients. The steering com-
mittee will repeatedly address this issue in meetings with
referring physicians. Finally, in a trial with a rare disease
such as infected necrotizing pancreatitis accrual is
expected to be difficult. If after the first year less than 85%
of the expected patients are recruited the study group will
invite (inter-)national centres to join PANTER.
Conclusion
PANTER is a randomised controlled multicenter trial set
out to reveal a reduction in major morbidity by introduc-
ing a minimally invasive 'step-up approach' instead of
maximal necrosectomy by laparotomy in patients with
(suspected) infected necrotizing pancreatitis. Results are
expected by 2008.
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UMC Utrecht; PB Soeters, University Hospital Maastricht.
Key staff at coordinating centre
HC van Santvoort (principal investigator), MGH Bes-
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Medical Center Utrecht.
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The last investigator per hospital is the local principal
investigator. All investigators are from departments of
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demic Medical Center Amsterdam: MJ Bruno (G), JS
Lameris (R), DJ Gouma, MA Boermeester; Leiden Univer-
sity Medical Center: A Haasnoot, AFM Schaapherder; Vrije
Universiteit Medical Center Amsterdam: CJ Mulder (G),
MA Cuesta; Canisius Wilhelmina Hospital Nijmegen: AC
Tan (G), PH Haarbrink (R), AHM Molenaar (R), C Ros-
man; Medical Center Rijnmond Zuid: E van der Harst;Page 9 of 10
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de Wit (G), CJHM van Laarhoven, St. Antonius Hospital
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